- Thermo Fisher’s adjusted earnings per share (EPS) for Q1 is $5.15, slightly beating the estimate of $5.11.
- Total revenue for the quarter is $10.36 billion, up by 0.2% compared to last year, surpassing the estimate of $10.23 billion.
- Life sciences segment revenue increased by 2.5% year-over-year to $2.34 billion, beating the estimate of $2.32 billion.
- Analytical instruments revenue rose by 1.8% year-over-year to $1.72 billion, exceeding the estimate of $1.69 billion.
- Specialty diagnostics had a revenue increase of 3.5% year-over-year, reaching $1.15 billion, above the estimated $1.09 billion.
- Lab products and services revenue fell by 1.5% year-over-year to $5.64 billion, but still surpassed the estimate of $5.57 billion.
- Eliminations revenue decreased by 4.8% year-over-year to negative $482 million.
- Adjusted operating income slightly decreased by 0.4% year-over-year to $2.27 billion, slightly below the estimate of $2.28 billion.
- Thermo Fisher’s adjusted operating margin was 21.9%, slightly lower than last year’s 22% and below the estimate of 22.3%.
- Analyst ratings include 26 buys, 5 holds, and no sells.
“`
Thermo Fisher Scientific Inc on Smartkarma
Analyst coverage of Thermo Fisher Scientific Inc on Smartkarma highlights the company’s recent financial performance and strategic initiatives. Baptista Research, in their report titled “Thermo Fisher Scientific: Will Its Shift Toward Contract Research and Manufacturing Pay Off? – Major Drivers,” notes a 5% year-over-year revenue growth in the fourth quarter of 2024, reaching $11.4 billion. Adjusted operating income increased by 7% to $2.72 billion, leading to an adjusted operating margin expansion of 50 basis points to 23.9%. Additionally, adjusted earnings per share (EPS) grew by 8% to $6.10.
In another report by Baptista Research, titled “Thermo Fisher Scientific: Expansion of Clinical Research & Pharma Services Integration Driving Our Bullishness! – Major Drivers,” the analysts highlight the company’s strong third-quarter results in 2024. Thermo Fisher Scientific reported quarterly revenue of $10.6 billion, with an adjusted operating income of $2.36 billion, representing an adjusted operating margin of 22.3%. The adjusted earnings per share (EPS) was reported at $5.28, showcasing the company’s ability to deliver consistent shareholder value through a mix of core business operations and strategic initiatives.
A look at Thermo Fisher Scientific Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Thermo Fisher Scientific Inc, a company known for manufacturing scientific instruments, consumables, and chemicals, has received an overall positive outlook based on Smartkarma’s Smart Scores. With an average score of 3 across various factors including value, growth, resilience, momentum, and dividend, Thermo Fisher Scientific Inc appears to be positioned well for long-term success.
While specific numbers are not mentioned, the company seems to strike a balance across different aspects, indicating a stable position in the market. Thermo Fisher Scientific Inc caters to a wide range of customers in the pharmaceutical, biotech, healthcare, education, and government sectors, showcasing its diversified and robust business model for sustained growth in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
